Perrigo Company PLC
Change company Symbol lookup
Select an option...
PRGO Perrigo Company PLC
OCUL Ocular Therapeutix Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
SALM Salem Media Group Inc
ASML ASML Holding NV
FUN Cedar Fair LP
Go

Health Care : Pharmaceuticals | Mid Cap Value
Based in Ireland
Company profile

Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the united States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.

Closing Price
$47.07
Day's Change
-1.31 (-2.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
48.53
Day's Low
46.59
Volume
(Heavy Day)
Volume:
1,853,520

10-day average volume:
923,251
1,853,520

Company Profile

Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the united States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.

Valuation Ratios

Price/Earnings (TTM)
26.90x
Price/Sales (TTM)
1.27x
Price/Book (MRQ)
1.09x
Price/Cash Flow (TTM)
10.15x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

August 2020
Current Month
3.9M
Previous Month
4.3M
Percent of Float
2.90%
Days to Cover
7.1167 Days

Share Information

PRGO is in a share class of common stock
Float
135.4M
Shares Outstanding
136.5M
Institutions Holding Shares
547
85.57%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Murray S. KesslerPres.
  • Raymond P. SilcockCFO
  • Robert Willis
  • Thomas M. FarringtonExec.VP
  • James E. DillardExec.VP

Address

Insider Trading

During the most recent quarter, 3K shares were bought, and 5K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.